Looking good medium to long term .
Phase 1 are small cohorts of patients with safety mainly the issue .
Phase 11 is where its get interesting .
Efficacy and Dosage with larger volumes of patients , as we can see below there have been issues ,
Botanix is working with multiple parties to test application of Permetrex™ technology to solve problems that have arisen in clinical studies
Phase 11 trials are crucial for the sp in both directions , if shown to have efficacy , the sp will be very much improved .
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $323.5M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.0¢ | $1.594M | 9.684M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 72 | 3839900 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 913601 | 19 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |